P2RY12 and atrial fibrillation: Second, the MATRIX‐2 trial (Monotherapy with P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation, NCT05955365) has commenced recruitment, aiming to evaluate the safety and efficacy of a monotherapy regimen with a P2Y12 inhibitor for 1 month, followed by direct oral anticoagulant (DOAC) monotherapy, compared to current standard care in atrial fibrillation patients undergoing PCI.